GlassScriptPhysician profile
Catherine Ferguson
NPI 1013520279
$3,705.05
in general payments reported to CMS, 2019-2025
26 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $1,966 · 2023: $281 · 2024: $329 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $605.58 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $477.64 | 2021-2023 | Breztri |
| Amgen INC. | $383.43 | 2021-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $298.87 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.99 | 2021-2022 | |
| Pfizer INC. | $263.99 | 2023-2025 | |
| Lilly USA, LLC | $175.11 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $166.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $165.18 | 2021-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $133.20 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $88.58 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.71 | 2022 | |
| Nestle Healthcare Nutrition INC. | $75.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $75.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.81 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $59.02 | 2021-2022 | |
| Astellas Pharma US INC | $57.94 | 2025 | Veozah |
| Viatris Specialty LLC | $55.33 | 2025 | Yupelri |
| Vanda Pharmaceuticals INC. | $48.73 | 2021 | |
| Sanofi Pasteur INC. | $29.00 | 2023 | |
| Esperion Therapeutics, INC. | $24.99 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $24.59 | 2022 | |
| Seqirus USA INC | $24.28 | 2025 | Fluad, Flucelvax |
| Nevro Corp. | $17.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.63 | 2025 | Xifaxan |
| Qiagen, LLC | $15.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.